Functional restoration of immune defects in STAT1 gain-of-function disease following stem cell gene editing.
Researchers corrected a dangerous genetic immune defect in patients' own blood cells using precision gene editing, restoring normal immune function without genetic damage.
Germline STAT1 gain-of-function mutations cause severe immunodeficiency with high allogeneic HSCT morbidity; this study demonstrates adenine base editing achieves >90% correction efficiency of the recurrent p.T385M mutation in patient-derived HSCs without significant on- or off-target genomic aberrations. Corrected HSCs retain multilineage capacity and engraft for 16 weeks in vivo, representing the first gene editing cure strategy for a dominant GOF immunodeficiency with potential applicability to other heterozygous dominant mutations.
What the study was
- Study design
- original_research
- Population
- STAT1 GOF patient-derived T cells and HSCs; humanized immunodeficient mouse engraftment model
- Category
- Gene Therapy / Rare Disease
- Maturity
- Exploratory
- Journal
- Blood
Why it surfaced
First application of adenine base editing to a dominant gain-of-function immunodeficiency; >90% correction efficiency in patient HSCs; Blood publication; UCL/Boston Children's consortium; could replace high-morbidity allogeneic HSCT; approach broadly applicable to other heterozygous dominant GOF disorders.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.